|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,650.00 KRW | +12.54% |
|
+22.70% | -35.29% |
Company Valuation: Onconic Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 |
|---|---|---|
| Market Cap 1 | 176,537 | 869,777 |
| Change | - | 392.69% |
| Enterprise Value (EV) 1 | 133,846 | 817,168 |
| Change | - | 510.53% |
| P/E | -16.5x | 56.2x |
| PBR | 3.15x | 12.1x |
| PEG | 0x | -0x |
| Capitalization / Revenue | 11.9x | 16.3x |
| EV / Revenue | 9.02x | 15.3x |
| EV / EBITDA | -30.8x | 62.2x |
| EV / EBIT | -27.9x | 64.8x |
| EV / FCF | - | - |
| FCF Yield | - | - |
| Dividend per Share 2 | - | - |
| Rate of return | - | - |
| EPS 2 | -247.5 | 347.9 |
| Distribution rate | - | - |
| Net sales 1 | 14,838 | 53,392 |
| EBITDA 1 | -4,345 | 13,148 |
| EBIT 1 | -4,798 | 12,619 |
| Net income 1 | -8,093 | 15,784 |
| Net Debt 1 | -42,691 | -52,609 |
| Reference price 2 | 4,085.00 | 19,550.00 |
| Nbr of stocks (in thousands) | 43,216 | 44,490 |
| Announcement Date | 3/1/25 | 3/1/26 |
1KRW in Million2KRW
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 403M | |
| 18.74x | 6.48x | 13.34x | 1.55% | 62.53B | |
| 30.63x | 7.64x | 23.53x | 0.05% | 52.43B | |
| -12.71x | 4.47x | -5.41x | -.--% | 23.1B | |
| -38.11x | 12.23x | -36.05x | -.--% | 21.4B | |
| 24.53x | 4.77x | 15.5x | -.--% | 17.76B | |
| 46.65x | 18.92x | 48.72x | 0.08% | 15.47B | |
| -734.33x | 34.85x | -3923.62x | -.--% | 14.68B | |
| 17.67x | 5.11x | 11.91x | -.--% | 14.08B | |
| -27.59x | 25.44x | -33.26x | -.--% | 12.62B | |
| Average | -74.95x | 13.32x | -431.70x | 0.19% | 23.45B | |
| Weighted average by Cap. | -34.42x | 10.48x | -237.80x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- A476060 Stock
- Valuation Onconic Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
